Is the increase in osteoporosis prevention a result of the audit?
Naunton
Mark
M
D000305:Adrenal Cortex Hormones / Q000009:adverse effects*; D019386:Alendronate / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002118:Calcium / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000592:standards; D012968:Etidronic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D008485:Medical Audit / Q000592:standards*; D009462:Neurology / Q000592:standards*; D010024:Osteoporosis / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control*; D017410:Practice Guidelines as Topic / Q000592:standards*; D000068296:Risedronic Acid; D006113:United Kingdom; D014807:Vitamin D / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D050071:Bone Density Conservation Agents; D014807:Vitamin D; D000068296:Risedronic Acid; D012968:Etidronic Acid; D002118:Calcium; D019386:Alendronate